|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 14:06
|
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies (Business Wire)
|
|
|
Support comes from new and existing investors, including life science, technology, growth, and sovereign wealth investors
Financing closely follows announcements of Iambic's clinical data for IAM1363 at the ESMO Congress and entry into a clinical collaboration with Jazz Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.
"We are thrilled to have the support of many outstanding and committed investors...
|
|
|
10.11.25 - 10:03
|
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron's and Bayer's injunction request in relation to manufacturing activities at Alvotech's CMO in the UK for Alvotech's biosimilar to Eylea® (AVT06). The decision will support commercial launches of Alvotech's biosimilar in the European Economic Area, the UK and other countries after the expiry date for Supplementary Protection Certificates (SPCs) for Eylea®, which is November 23, 2025....
|
|
|
10.11.25 - 10:03
|
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron's and Bayer's injunction request in relation to manufacturing activities at Alvotech's CMO in the UK for Alvotech's biosimilar to Eylea® (AVT06). The decision will support commercial launches of Alvotech's biosimilar in the European Economic Area, the UK and other countries after the expiry date for Supplementary Protection Certificates (SPCs) for Eylea®, which is November 23, 2025....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
